PTGX Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 77.17% compared to Protagonist Therapeutics's net margin of 16.72%. Protagonist Therapeutics's return on equity of 52.01% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Protagonist Therapeutics has a consensus price target of $69.10, signalling upside risk potential of 62.13%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.77 which suggests that it could grow by 70.3%. Given that Biomarin Pharmaceutical has higher upside potential than Protagonist Therapeutics, analysts believe Biomarin Pharmaceutical is more attractive than Protagonist Therapeutics.

Protagonist Therapeutics has a beta of 2.305, which suggesting that the stock is 130.476% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.812%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $170.6M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Protagonist Therapeutics's net income of $131.7M is higher than Biomarin Pharmaceutical's net income of $124.9M. Notably, Protagonist Therapeutics's price-to-earnings ratio is 10.15x while Biomarin Pharmaceutical's PE ratio is 25.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 6.21x versus 3.95x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Checkpoint Therapeutics has a net margin of 77.17% compared to Protagonist Therapeutics's net margin of -16268.29%. Protagonist Therapeutics's return on equity of 52.01% beat Checkpoint Therapeutics's return on equity of --.

Protagonist Therapeutics has a consensus price target of $69.10, signalling upside risk potential of 62.13%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 8.61%. Given that Protagonist Therapeutics has higher upside potential than Checkpoint Therapeutics, analysts believe Protagonist Therapeutics is more attractive than Checkpoint Therapeutics.

Protagonist Therapeutics has a beta of 2.305, which suggesting that the stock is 130.476% more volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.135%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $170.6M, which are larger than Checkpoint Therapeutics quarterly revenues of $41K. Protagonist Therapeutics's net income of $131.7M is higher than Checkpoint Therapeutics's net income of -$9.7M. Notably, Protagonist Therapeutics's price-to-earnings ratio is 10.15x while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 6.21x versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 77.17% compared to Protagonist Therapeutics's net margin of 23.56%. Protagonist Therapeutics's return on equity of 52.01% beat Gilead Sciences's return on equity of 2.5%.

Protagonist Therapeutics has a consensus price target of $69.10, signalling upside risk potential of 62.13%. On the other hand Gilead Sciences has an analysts' consensus of $112.46 which suggests that it could grow by 8.52%. Given that Protagonist Therapeutics has higher upside potential than Gilead Sciences, analysts believe Protagonist Therapeutics is more attractive than Gilead Sciences.

Protagonist Therapeutics has a beta of 2.305, which suggesting that the stock is 130.476% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.99% to investors and pays a quarterly dividend of $0.79 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $170.6M, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Protagonist Therapeutics's net income of $131.7M is lower than Gilead Sciences's net income of $1.8B. Notably, Protagonist Therapeutics's price-to-earnings ratio is 10.15x while Gilead Sciences's PE ratio is 280.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 6.21x versus 4.53x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 77.17% compared to Protagonist Therapeutics's net margin of 15.24%. Protagonist Therapeutics's return on equity of 52.01% beat Johnson & Johnson's return on equity of 19.98%.

Protagonist Therapeutics has a consensus price target of $69.10, signalling upside risk potential of 62.13%. On the other hand Johnson & Johnson has an analysts' consensus of $169.87 which suggests that it could grow by 11.96%. Given that Protagonist Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Protagonist Therapeutics is more attractive than Johnson & Johnson.

Protagonist Therapeutics has a beta of 2.305, which suggesting that the stock is 130.476% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.27% to investors and pays a quarterly dividend of $1.24 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Protagonist Therapeutics quarterly revenues are $170.6M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Protagonist Therapeutics's net income of $131.7M is lower than Johnson & Johnson's net income of $3.4B. Notably, Protagonist Therapeutics's price-to-earnings ratio is 10.15x while Johnson & Johnson's PE ratio is 26.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 6.21x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.